Additional medical conditions-Chest pain (angina) or prior heart attack (MI) Posts on Medivizor

Posted by Medivizor on Apr 22, 2016 in Prostate cancer | 0 comments

In a nutshell This study investigated the impact of metabolic syndrome on treatment outcome with abiraterone acetate (Zytiga) for hormone-resistant prostate cancer. Researchers concluded that metabolic syndrome has an adverse outcome on disease progression in advanced prostate cancer. Some background Hormone therapy is a common treatment used in...